JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M704576200 on November 15, 2007

J. Biol. Chem., Vol. 283, Issue 4, 1839-1847, January 25, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/4/1839    most recent
M704576200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christoffersen, C.
Right arrow Articles by Nielsen, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christoffersen, C.
Right arrow Articles by Nielsen, L. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice*Formula

Christina Christoffersen{ddagger}1, Matti Jauhiainen§, Markus Moser, Bo Porse{ddagger}, Christian Ehnholm§, Michael Boesl, Björn Dahlbäck||, and Lars Bo Nielsen{ddagger}**2

From the {ddagger}Department of Clinical Biochemistry, Rigshospitalet, and the **Department of Biomedical Sciences, University of Copenhagen, DK-2100 Copenhagen Denmark, the §Department of Molecular Medicine, National Public Health Institute, Biomedicum, 00290, Helsinki, Finland, the Department of Molecular Medicine, Max Planck Institute of Biochemistry, 82152, Martinsried, Germany, and the ||Department of Laboratory Medicine, Division of Clinical Chemistry, University of Lund, University Hospital, 20502, Malmö, Sweden

To investigate the role of apoM in high density lipoprotein (HDL) metabolism and atherogenesis, we generated human apoM transgenic (apoM-Tg) and apoM-deficient (apoM–/–) mice. Plasma apoM was predominantly associated with 10–12-nm {alpha}-migrating HDL particles. Human apoM overexpression (11-fold) increased plasma cholesterol concentration by 13–22%, whereas apoM deficiency decreased it by 17–21%. The size and charge of apoA-I-containing HDL in plasma were not changed in apoM-Tg or apoM–/– mice. However, in plasma incubated at 37 °C, lecithin:cholesterol acyltransferase-dependent conversion of {alpha}- to pre-{alpha}-migrating HDL was delayed in apoM-Tg mice. Moreover, lecithin: cholesterol acyltransferase-independent generation of pre-β-migrating apoA-I-containing particles in plasma was increased in apoM-Tg mice (4.2 ± 1.1%, p = 0.06) and decreased in apoM–/– mice (0.5 ± 0.3%, p = 0.03) versus controls (1.8 ± 0.05%). In the setting of low density lipoprotein receptor deficiency, apoM-Tg mice with ~2-fold increased plasma apoM concentrations developed smaller atherosclerotic lesions than controls. The effect of apoM on atherosclerosis may be facilitated by enzymatic modulation of plasma HDL particles, increased cholesterol efflux from foam cells, and an antioxidative effect of apoM-containing HDL.


Received for publication, June 4, 2007 , and in revised form, October 22, 2007.

* This work was supported by Danish Heart Foundation Grants 02-1-2-24-22980 (to L. B. N.) and 06-4-B522-A918-22286 (to C. C.), Rigshospitalet, University of Copenhagen (to L. B. N.), Gerda and Aage Haensch's Foundation, Denmark (to C. C.), Sweden Research Council Grant 07143 and the Sweden Heart-Lung Foundation, Söderbergs Stiftelse, University Hospital in Malmö Foundation (to B. D.), Research Council for Health, Academy of Finland, Grant 114484 (to M. J.), the Finnish Foundation for Cardiovascular Research (to M. J.), and the Sigrid Juselius Foundation (to M. J. and C. E.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–4 and Tables 1–3.

1 To whom correspondence may be addressed: Dept. of Clinical Biochemistry, KB3011, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel.: 45-3545-3011; Fax: 45-3545-2524; E-mail: Christina.christoffersen{at}rh.regionh.dk. 2 To whom correspondence may be addressed: Dept. of Clinical Biochemistry, KB3011, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel.: 45-3545-3011; Fax: 45-3545-2524; E-mail: larsbo{at}rh.dk.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Wolfrum, J. J. Howell, E. Ndungo, and M. Stoffel
Foxa2 Activity Increases Plasma High Density Lipoprotein Levels by Regulating Apolipoprotein M
J. Biol. Chem., June 13, 2008; 283(24): 16940 - 16949.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.